Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We presen...

Podrobná bibliografie
Hlavní autoři:	Moorman, A, Harrison, C, Buck, G, Richards, S, Secker-Walker, L, Martineau, M, Vance, G, Cherry, A, Higgins, R, Fielding, A, Foroni, L, Paietta, E, Tallman, MS, Litzow, MR, Wiernik, P, Rowe, J, Goldstone, A, Dewald, G
Médium:	Journal article
Jazyk:	English
Vydáno:	2007

Podobné jednotky

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
Autor: Moorman, A, a další
Vydáno: (2005)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Autor: Ganzel, C, a další
Vydáno: (2020)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
Autor: Paietta, E, a další
Vydáno: (2008)

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
Autor: Fielding, A, a další
Vydáno: (2009)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Autor: Fielding, A, a další
Vydáno: (2014)

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
Autor: Fielding, A, a další
Vydáno: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
Autor: Fielding, A, a další
Vydáno: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
Autor: Fielding, A, a další
Vydáno: (2010)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
Autor: Mansour, MR, a další
Vydáno: (2009)

Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study
Autor: Fielding, A, a další
Vydáno: (2007)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Autor: Rowe, J, a další
Vydáno: (2008)

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
Autor: Sive, J, a další
Vydáno: (2012)

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
Autor: David I. Marks, a další
Vydáno: (2013-06-01)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
Autor: Goldstone, A, a další
Vydáno: (2001)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
Autor: Fielding, A, a další
Vydáno: (2007)

Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol.
Autor: Mansour, MR, a další
Vydáno: (2008)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia
Autor: Moorman, A, a další
Vydáno: (2007)

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
Autor: Lazarus, H, a další
Vydáno: (2006)

Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993).
Autor: Rowe, J, a další
Vydáno: (2003)

Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
Autor: Kumar, A, a další
Vydáno: (2016)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
Autor: Rowe, J, a další
Vydáno: (2005)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia
Autor: Moorman, A, a další
Vydáno: (2007)

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
Autor: Marks, D, a další
Vydáno: (2009)

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
Autor: Goldstone, A, a další
Vydáno: (1999)

The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study
Autor: Goldstone, A, a další
Vydáno: (2004)

Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)
Autor: Lazarus, H, a další
Vydáno: (2004)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups
Autor: Lrrzow, MR, a další
Vydáno: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
Autor: Lrrzow, MR, a další
Vydáno: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
Autor: Lrrzow, MR, a další
Vydáno: (2010)

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Autor: Goldstone, A, a další
Vydáno: (2008)

Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.
Autor: Chopra, R, a další
Vydáno: (2003)

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
Autor: Rowe, J, a další
Vydáno: (2001)

The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
Autor: Patel, B, a další
Vydáno: (2005)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
Autor: Patel, B, a další
Vydáno: (2010)

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
Autor: Ramanujachar, R, a další
Vydáno: (2007)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Autor: Sive, J, a další
Vydáno: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Autor: Sive, J, a další
Vydáno: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
Autor: Sive, J, a další
Vydáno: (2010)

Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.
Autor: Rai, L, a další
Vydáno: (2010)

Minimal residual disease is a significant predictor of treatment failure in B lineage adult ALL: final results of the international trial UKALL XII:ECOG 2993
Autor: Patel, B, a další
Vydáno: (2009)